Corporate Action29 Oct 2020 12:27
Received another message regarding the demerge, not sure if someone has seen it.
TIZIANA LIFE SCIENCES - Important Information
Demerger Update.
1 New Accustem Sciences (Accustem) share for each Existing Tiziana Life Sciences (Tiziana) share held on the Ex-entitlement Date, 2nd November 2020.
Important Information & Other Key Dates:
Following our previous communication 30th September 2020 we have received information that the Ex-entitlement to receive New Accustem shares is 2nd November 2020.
On 16th September 2020, Tiziana announced that following a strategic review of its clinical trial programs and core focus, the Company intended to demerge its StemPrintER and SPARE genomics-based personalised medicine business, Accustem, into a separate and independent listed Company.
The Demerger received shareholder approval at the General Meeting held on 2nd October 2020.
Subsequently, the Demerger is expected to become effective on 30th October 2020 and the Ex-entitlement for the New Accustem shares is expected to be 2nd November 2020. However, it is not yet known when the New Accustem shares will be received.
Following completion of the Demerger, it is not yet known when the New Accustem will be admitted to trading on the Official List of the London Stock Exchange (LSE). Please note that whilst the New Accustem shares will be reflected on your account, the shares will not listed on a recognised stock exchange and therefore you are not able to sell or otherwise trade the Accustem shares through our nominee service.
Unless you hold your shares in a ShareBuilder account, no fractions of shares will be issued. Any resulting cash entitlements will be dealt with in accordance with our Terms & Conditions.
Should you retain your holding in Tiziana we will notify you when the New Accustem shares have been credited to your account.
If you wish to find more information about the Demerger, please visit the Tiziana website, www.tizianalifesciences.com/